Cargando…

Bortezomib sensitivity is tissue dependent and high expression of the 20S proteasome precludes good response in malignant pleural mesothelioma

BACKGROUND: Bortezomib is an approved proteasome inhibitor for the treatment of certain lymphoma subtypes. Two clinical trials investigated bortezomib in patients with malignant pleural mesothelioma (MPM) and failed to improve outcome. We present a potential explanation for this event. METHODS: 171...

Descripción completa

Detalles Bibliográficos
Autores principales:	Walter, Robert Fred Henry, Sydow, Saskia Roxanne, Berg, Erika, Kollmeier, Jens, Christoph, Daniel Christian, Christoph, Sandra, Eberhardt, Wilfried Ernst Erich, Mairinger, Thomas, Wohlschlaeger, Jeremias, Schmid, Kurt Werner, Mairinger, Fabian Dominik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6765394/ https://www.ncbi.nlm.nih.gov/pubmed/31576173 http://dx.doi.org/10.2147/CMAR.S194337

Ejemplares similares

Immunohistochemically detectable metallothionein expression in malignant pleural mesotheliomas is strongly associated with early failure to platin-based chemotherapy
por: Mairinger, Fabian D., et al.
Publicado: (2018)

Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro
por: Borchert, Sabrina, et al.
Publicado: (2019)

Inhibition of MDM2 via Nutlin-3A: A Potential Therapeutic Approach for Pleural Mesotheliomas with MDM2-Induced Inactivation of Wild-Type P53
por: Walter, Robert F. H., et al.
Publicado: (2018)

Cancer-Associated Fibroblasts Influence Survival in Pleural Mesothelioma: Digital Gene Expression Analysis and Supervised Machine Learning Model
por: Borchert, Sabrina, et al.
Publicado: (2023)

Impact of metallothionein-knockdown on cisplatin resistance in malignant pleural mesothelioma
por: Borchert, Sabrina, et al.
Publicado: (2020)

One Third of Malignant Pleural Mesothelioma Shows High Immunohistochemical Expression of MSLN or CXCR4 Which Indicates Potent Candidates for Endo-Radiotherapy
por: Hager, Thomas, et al.
Publicado: (2023)

microRNAs are differentially regulated between MDM2-positive and negative malignant pleural mesothelioma
por: Walter, Robert Fred Henry, et al.
Publicado: (2016)

Mitogen signal-associated pathways, energy metabolism regulation, and mediation of tumor immunogenicity play essential roles in the cellular response of malignant pleural mesotheliomas to platinum-based treatment: a retrospective study
por: Mathilakathu, Alexander, et al.
Publicado: (2021)

Processing Escape Mechanisms Through Altered Proteasomal Cleavage of Epitopes Affect Immune Response in Pulmonary Neuroendocrine Tumors
por: Wessolly, Michael, et al.
Publicado: (2018)

Digital Gene Expression Analysis of Epithelioid and Sarcomatoid Mesothelioma Reveals Differences in Immunogenicity
por: Brcic, Luka, et al.
Publicado: (2021)

Screening of Pleural Mesothelioma Cell Lines for Kinase Activity May Identify New Mechanisms of Therapy Resistance in Patients Receiving Platin-Based Chemotherapy
por: Borchert, Sabrina, et al.
Publicado: (2019)

Induction of metallothionein expression by supplementation of zinc induces resistance against platinum-based treatment in malignant pleural mesothelioma
por: Wyrich, Martine, et al.
Publicado: (2023)

Folic acid phenotype (FAP) is a superior biomarker predicting response to pemetrexed-based chemotherapy in malignant pleural mesothelioma
por: Mairinger, Fabian Dominik, et al.
Publicado: (2017)

MDM2 is an important prognostic and predictive factor for platin–pemetrexed therapy in malignant pleural mesotheliomas and deregulation of P14/ARF (encoded by CDKN2A) seems to contribute to an MDM2-driven inactivation of P53
por: Walter, R F H, et al.
Publicado: (2015)

Screening of Pleural Mesotheliomas for DNA-damage Repair Players by Digital Gene Expression Analysis Can Enhance Clinical Management of Patients Receiving Platin-Based Chemotherapy
por: Walter, Robert Fred Henry, et al.
Publicado: (2016)

Cancer-Associated Fibroblasts Regulate Kinase Activity in Mesothelioma Cell Lines via Paracrine Signaling and Thereby Dictate Cell Faith and Behavior
por: Mathilakathu, Alexander, et al.
Publicado: (2022)

Proteasome stress sensitizes malignant pleural mesothelioma cells to bortezomib-induced apoptosis
por: Cerruti, Fulvia, et al.
Publicado: (2017)

Gene Expression Analysis of the 26S Proteasome Subunit PSMB4 Reveals Significant Upregulation, Different Expression and Association with Proliferation in Human Pulmonary Neuroendocrine Tumours
por: Mairinger, Fabian Dominik, et al.
Publicado: (2014)

Identification of deregulation of apoptosis and cell cycle in neuroendocrine tumors of the lung via NanoString nCounter expression analysis
por: Walter, Robert Fred Henry, et al.
Publicado: (2015)

Mutational analysis of pulmonary tumours with neuroendocrine features using targeted massive parallel sequencing: a comparison of a neglected tumour group
por: Vollbrecht, Claudia, et al.
Publicado: (2015)

Folic-acid metabolism and DNA-repair phenotypes differ between neuroendocrine lung tumors and associate with aggressive subtypes, therapy resistance and outcome
por: Henry Walter, Robert Fred, et al.
Publicado: (2016)

A Novel Epitope Quality-Based Immune Escape Mechanism Reveals Patient’s Suitability for Immune Checkpoint Inhibition
por: Wessolly, Michael, et al.
Publicado: (2020)

Massive parallel sequencing and digital gene expression analysis reveals potential mechanisms to overcome therapy resistance in pulmonary neuroendocrine tumors
por: Walter, Robert Fred Henry, et al.
Publicado: (2016)

Fibroblast activation protein-α expression in fibroblasts is common in the tumor microenvironment of colorectal cancer and may serve as a therapeutic target
por: Greimelmaier, K., et al.
Publicado: (2023)

Activation of Angiogenesis Differs Strongly Between Pulmonary Carcinoids and Neuroendocrine Carinomas and Is Crucial for Carcinoid Tumourgenesis
por: Mairinger, Fabian D., et al.
Publicado: (2014)

ACTB, CDKN1B, GAPDH, GRB2, RHOA and SDCBP Were Identified as Reference Genes in Neuroendocrine Lung Cancer via the nCounter Technology
por: Walter, Robert Fred Henry, et al.
Publicado: (2016)

Digital gene expression analysis of NSCLC-patients reveals strong immune pressure, resulting in an immune escape under immunotherapy
por: Wessolly, Michael, et al.
Publicado: (2022)

Determinants of plasma calretinin in patients with malignant pleural mesothelioma
por: Lehnert, Martin, et al.
Publicado: (2020)

T lymphocytes export proteasomes by way of microparticles: a possible mechanism for generation of extracellular proteasomes
por: Bochmann, Isabel, et al.
Publicado: (2014)

Gemcitabine combined with oxaliplatin in pretreated patients with malignant pleural mesothelioma: an observational study
por: Xanthopoulos, Athanasios, et al.
Publicado: (2008)

Bortezomib Warhead-Switch Confers Dual Activity against Mycobacterial Caseinolytic Protease and Proteasome and Selectivity against Human Proteasome
por: Moreira, Wilfried, et al.
Publicado: (2017)

Bortezomib Amplifies Effect on Intracellular Proteasomes by Changing Proteasome Structure()
por: Pitcher, David S., et al.
Publicado: (2015)

The resistance mechanisms of proteasome inhibitor bortezomib
por: Lü, Shuqing, et al.
Publicado: (2013)

Proteasomal Processing Immune Escape Mechanisms in Platinum-Treated Advanced Bladder Cancer
por: Wessolly, Michael, et al.
Publicado: (2022)

Lung adenocarcinoma patients with malignant pleural effusions in hot adaptive immunity status have a longer overall survival
por: Wu, Cheng-Guang, et al.
Publicado: (2022)

Intra-patient comparison of parietal pleural biopsies by rigid forceps, flexible forceps and cryoprobe obtained during medical thoracoscopy: a prospective series of 80 cases with pleural effusion
por: Wurps, H., et al.
Publicado: (2016)

Integrated Clinical, Molecular and Immunological Characterization of Pulmonary Sarcomatoid Carcinomas Reveals an Immune Escape Mechanism That May Influence Therapeutic Strategies
por: Stephan-Falkenau, Susann, et al.
Publicado: (2023)

Malignant pleural mesothelioma
por: Rao, Sukhesh
Publicado: (2009)

Survival in Good Performance Malignant Pleural Mesothelioma Patients; Prognostic Factors and Predictors of Response
por: Rahouma, Mohamed, et al.
Publicado: (2017)

Biomarker-guided targeted and immunotherapies in malignant pleural mesothelioma
por: Yang, Haitang, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_k6oiernb6or24c5aidtg2vbilq